InDex Pharmaceuticals Holding AB (publ) interim report January – March 2023
Positive results from pharmacokinetic study with cobitolimod“We are very excited that the pharmacokinetic study could confirm a low systemic uptake of the higher dose of 500 mg cobitolimod, and that it was well tolerated with no serious adverse events reported in the study,” said Jenny Sundqvist, CEO of InDex Pharmaceuticals. “One of the potential benefits of a locally acting treatment in the colon is low systemic exposure, and with these results we can add another building block to support our excellent safety profile.” Period January – March 2023 · Net sales amounted to SEK 0.0 (0.